Last reviewed · How we verify

NCT05920473

Efficacy and Safety Study: Repetitive Transcranial Magnetic Stimulation (rTMS) for Treating Movement Disorders in Patients With Intracranial Hemorrhage (ICH).

Status unknown NA Last updated 27 June 2023
What this trial tests

NA trial testing rTMS with Magstim Rapid 2 magnetic stimulation device in Intracerebral Hemorrhage in 130 participants. Status unknown.

Timeline
1 July 2023
Primary endpoint
31 December 2024
31 December 2024

Quick facts

Lead sponsorBeijing Tiantan Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment130
Start date1 July 2023
Primary completion31 December 2024
Estimated completion31 December 2024
Sites3 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Tiantan Hospital

Who can join

Adults 45 to 65, any sex, with Intracerebral Hemorrhage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot study aims to assess the effectiveness and safety of rTMS in the treatment of movement disorders in patients with ICH.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Intracerebral Hemorrhage

Currently open trials in the same condition.

Other Beijing Tiantan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05920473.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing